{"product_id":"nanoparticles-for-brain-aneurysms-new-hope-for-treatment","title":"Nanoparticles for Brain Aneurysms: New Hope for Treatment","description":"\u003cp\u003eThis review examines how nanoparticles—microscopic delivery vehicles—could improve treatment for cerebral aneurysms (bulging, weakened areas in brain arteries). The authors describe how aneurysms form through hemodynamic stress (force from blood flow), endothelial dysfunction (damage to the artery's inner lining), and inflammation. They compare brain aneurysms with aortic aneurysms to find shared mechanisms that could guide new treatments. The review highlights nanocarriers such as liposomes and polymeric nanoparticles. These nanocarriers can deliver drugs like Edaravone and Tanshinone IIA directly to aneurysm walls. This delivery potentially overcomes the blood–brain barrier and reduces side effects.\u003c\/p\u003e\n\n\u003ch1\u003eNanoparticles for Brain Aneurysms: New Hope for Treatment\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n\u003cli\u003e\u003ca href=\"#background\"\u003eBackground: What Are Cerebral Aneurysms?\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#pathophysiology\"\u003eHow Aneurysms Develop: The Role of Blood Flow and Inflammation\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#histopathology\"\u003eWhat Aneurysms Look Like Under the Microscope\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#nanocarriers\"\u003eNanocarriers: Tiny Vehicles for Drug Delivery\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#monitoring\"\u003eMonitoring and Identifying Aneurysms at Risk of Rupture\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations and Challenges\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Future Directions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eCerebral aneurysms are bulges in brain arteries, most often at branching points, and affect about 1% to 5% of people.\u003c\/li\u003e\n\u003cli\u003eUnruptured aneurysms carry an annual rupture risk of about 0.7%, which increases with size, location, high blood pressure, and smoking.\u003c\/li\u003e\n\u003cli\u003eNanocarriers like liposomes and polymeric nanoparticles can deliver drugs such as Edaravone and Tanshinone IIA directly to aneurysm walls in research.\u003c\/li\u003e\n\u003cli\u003eIn a study, ferumoxytol, an iron oxide nanoparticle, accumulated in macrophage-rich aneurysm walls and its presence within 24 hours was linked to high rupture risk within six months.\u003c\/li\u003e\n\u003cli\u003eMost studies were in animals or labs; more research is needed to confirm safety and effectiveness in human patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: What Are Cerebral Aneurysms?\u003c\/h2\u003e\n\n\u003cp\u003eCerebral aneurysms are abnormal dilations (bulging areas) of arteries in the brain. They most often form at the bifurcations (branching points) of the Circle of Willis, a ring of blood vessels at the base of the brain. Most cerebral aneurysms occur in the anterior circulation, which supplies the front part of the brain.\u003c\/p\u003e\n\n\u003cp\u003eThese aneurysms develop in people who have certain risk factors. These risk factors include atherosclerosis (hardening of the arteries), alcohol abuse, smoking, and hypertension (high blood pressure).\u003c\/p\u003e\n\n\u003cp\u003eThe rupture (bursting) of an aneurysm has a very high rate of death and disability. When an aneurysm ruptures, it causes a subarachnoid hemorrhage (bleeding into the space around the brain).\u003c\/p\u003e\n\n\u003cp\u003eCerebral aneurysms have a prevalence (how common they are) ranging from 1% to 5% in the general population. This means that about 1 to 5 people out of every 100 have a cerebral aneurysm. The annual risk of rupture is approximately 0.7% for unruptured aneurysms. However, this risk increases significantly with the size of the aneurysm, its location, and patient-specific factors such as hypertension and smoking history.\u003c\/p\u003e\n\n\u003cp\u003eIn recent years, current practices for managing unruptured intracranial aneurysms have increasingly favored endovascular treatment options. Endovascular treatment means treating the aneurysm from inside the blood vessel. For a ruptured aneurysm, endovascular treatment has become the primary method of management.\u003c\/p\u003e\n\n\u003cp\u003eThis article explores the potential of using nanoparticles to treat intracranial aneurysms. By comparing brain aneurysms with other types of aneurysms, the authors try to find common ground and differences that could guide better treatment options. By learning from how other aneurysms are treated, the authors seek to find new ideas that could be applied to brain aneurysms.\u003c\/p\u003e\n\n\u003ch2 id=\"pathophysiology\"\u003eHow Aneurysms Develop: The Role of Blood Flow and Inflammation\u003c\/h2\u003e\n\n\u003cp\u003eAneurysms most frequently develop in areas where blood flow causes high wall shear stress (WSS). Wall shear stress is the force that flowing blood exerts on the artery wall. This is why aneurysms commonly occur at vessel bifurcations (branching points).\u003c\/p\u003e\n\n\u003cp\u003eIt is believed that high wall shear stress is involved in initiating cerebral aneurysm formation. In contrast, low wall shear stress leads to the progressive development of aneurysms through induced proinflammatory conditions. Low wall shear stress has a negative effect on endothelial cells (the cells lining the inside of blood vessels). Low wall shear stress is an important contributor to arterial wall remodeling.\u003c\/p\u003e\n\n\u003cp\u003eThe frequency of a subarachnoid hemorrhage due to aneurysm rupture is estimated to be 10 to 15 cases per 100,000 individuals per year. Mortality rates for subarachnoid hemorrhage are as high as 50%.\u003c\/p\u003e\n\n\u003cp\u003eThe reduction in wall shear stress can serve as a predictive parameter indicating the risk of aneurysm rupture. For instance, studies have demonstrated that intracranial aneurysms located in the internal carotid artery are associated with a higher likelihood of aneurysm rupture. The internal carotid artery is an area characterized by low wall shear stress.\u003c\/p\u003e\n\n\u003cp\u003eLow wall shear stress causes changes in the endothelium (the inner lining of the artery). These changes include alterations in secretion and disorganization of the endothelium's structure. One of the essential problems is a decrease in vasodilatory and antioxidant molecules (substances that widen blood vessels and protect against damage). At the same time, there is an increase in the production of vasoconstrictive molecules (substances that narrow blood vessels).\u003c\/p\u003e\n\n\u003cp\u003eMoreover, low shear stress favors apoptosis (programmed cell death). Disturbed shear stress causes an increase in endothelial turnover (the rate at which endothelial cells are replaced). Laminar shear stress (smooth, steady blood flow) induces cell cycle arrest in the G0 or G1 phases.\u003c\/p\u003e\n\n\u003cp\u003eThere is evidence suggesting that this endothelial dysfunction caused by hemodynamic stress leads to aneurysm formation. Cells begin to produce inflammatory molecules that result in the recruitment of macrophages (a type of immune cell).\u003c\/p\u003e\n\n\u003cp\u003eThis recruitment of leukocytes (white blood cells) leads to the amplification of inflammation through the secretion of inflammatory molecules. Matrix metalloproteinases MMP-2 and MMP-9 play an important role. Their production is stimulated by IL-8 and TNF-alpha. It is worth noting that endothelial cells exposed to hemodynamic stress also produce TNF-alpha.\u003c\/p\u003e\n\n\u003cp\u003eEndothelial dysfunction is characterized by macrophage infiltration. This leads to an inflammatory response that exacerbates aneurysm development.\u003c\/p\u003e\n\n\u003cp\u003eTNF-alpha is a key proinflammatory cytokine (a signaling molecule that promotes inflammation) involved in various inflammatory processes. TNF-alpha stimulates the production of MMP-9 in several cell types, including monocytes and macrophages. MMP-9, along with MMP-2, contributes to the degradation of the extracellular matrix and basement membrane. This degradation facilitates the migration of inflammatory cells to the site of inflammation.\u003c\/p\u003e\n\n\u003cp\u003eIn a study conducted by Aoki et al., it was highlighted that the NF-κB pathway can be activated by TNF-alpha. This was evidenced by the fact that in TNFR-1 heterozygous and TNFR1-deficient mice, the incidence of intracranial aneurysms was reduced compared to wild-type mice. Wall shear stress can also induce PGE2-EP2 receptor signaling. This activates NF-κB in endothelial cells, leading to chronic inflammation in the walls of the aneurysm.\u003c\/p\u003e\n\n\u003cp\u003eOne of the most significant roles of NF-κB is its involvement in the development of intracranial aneurysms. NF-κB does this by promoting the recruitment and activation of macrophages. NF-κB transactivates genes that are crucial for cell adhesion, such as Vascular Cell Adhesion Molecule-1 (VCAM-1). NF-κB also transactivates chemotactic molecules like Monocyte Chemoattracting Protein-1 (MCP-1).\u003c\/p\u003e\n\n\u003cp\u003eIn addition to increasing the expression of these molecules, NF-κB also regulates pro-inflammatory genes. These genes include Interleukin-1 beta (IL-1β), Cyclooxygenase-2 (COX-2), and Inducible Nitric Oxide Synthase (iNOS).\u003c\/p\u003e\n\n\u003cp\u003eNF-κB is also involved in the disorganization of the wall matrix. First, NF-κB decreases the expression of lysyl oxidase and procollagens. Second, NF-κB increases the expression of metalloproteinases.\u003c\/p\u003e\n\n\u003cp\u003eIn addition to endothelial damage, aneurysms also involve the impairment of smooth muscle cells. Due to vascular inflammation, a phenotypic transition of vascular smooth muscle cells occurs. The muscle cells contract the vessel of the aneurysm. These smooth muscle cells change their contractility by decreasing the number of myofilaments. Some researchers have argued that the phenotypic transition of smooth muscle cells into macrophage-like cells plays a role in the inflammatory process.\u003c\/p\u003e\n\n\u003cp\u003eAt the neck of the aneurysm, platelet-derived growth factor (PDGF)-BB is expressed in endothelial cells where high wall shear stress exists. This molecule assists in the modification of smooth muscle cells in the vessel.\u003c\/p\u003e\n\n\u003cp\u003eSome studies have suggested that the loss of collagen in the aneurysm wall is associated with an increased risk of rupture. Additionally, loss of collagen is associated with a decrease in the levels of MMP2 and MMP9 in the aneurysm walls. Thus, from these studies, it appears that macrophages may not be the only key factor in the development of aneurysms.\u003c\/p\u003e\n\n\u003ch2 id=\"histopathology\"\u003eWhat Aneurysms Look Like Under the Microscope\u003c\/h2\u003e\n\n\u003cp\u003eThe wall of an aneurysm undergoes significant modifications due to inflammatory processes. This degeneration intensifies as it progresses from the neck of the aneurysm towards the dome. Notably, the loss of smooth muscle cells is most pronounced at the dome level. These changes correlate with the fact that the dome of the aneurysm is the most common site of rupture.\u003c\/p\u003e\n\n\u003cp\u003eIn the wall, the recruitment of fibroblasts occurs, and the smooth muscle cells become disorganized. The vessel wall thickens and becomes hypocellular (having fewer cells). The vessel wall is characterized by an increase in collagen content. At the same time, organizing thrombi (blood clots) develop within the lumen (the hollow space) of the vessel.\u003c\/p\u003e\n\n\u003cp\u003eAs the inflammation progresses, the wall becomes irregular and thin. The wall has sparse layers of collagen and persistent hypocellularity.\u003c\/p\u003e\n\n\u003cp\u003eA study by Frösen et al. classified 66 aneurysm domes into 4 qualitative morphological groups. These groups are based on how the aneurysm wall looks under a microscope:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eType A:\u003c\/strong\u003e An endothelialized wall with linearly aligned smooth muscle cells. The rupture risk for this type is 42%.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eType B:\u003c\/strong\u003e A thickened wall with disorganized smooth muscle cells. The rupture risk for this type is 55%.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eType C:\u003c\/strong\u003e A hypocellular wall with myointimal hyperplasia (thickening of the inner layer) or organizing thrombosis. The rupture risk for this type is 64%.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eType D:\u003c\/strong\u003e An extremely thin thrombosis-lined hypocellular wall. The rupture risk for this type is 100%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis classification made by Frösen shows us the structural characteristics of intracranial aneurysms that can lead to their rupture. This study demonstrates the correlation between aneurysm morphology (shape and structure) and its risk of rupture. Type D has the highest risk of rupture.\u003c\/p\u003e\n\n\u003cp\u003eThe ruptured aneurysm wall is more often characterized by being disorganized, thinner, and hypocellular. A ruptured aneurysm wall also has an organized thrombus present.\u003c\/p\u003e\n\n\u003ch2 id=\"nanocarriers\"\u003eNanocarriers: Tiny Vehicles for Drug Delivery\u003c\/h2\u003e\n\n\u003cp\u003eNanocarriers are colloidal systems that facilitate the targeted delivery of therapeutic agents. They provide a means to overcome many limitations associated with traditional drug delivery methods. These limitations include poor solubility, rapid degradation, and nonspecific distribution.\u003c\/p\u003e\n\n\u003cp\u003eCommon types of nanocarriers include liposomes, micelles, polymeric nanoparticles, and dendrimers. These systems range in size from 1 to 1000 nanometers (nm). They are engineered to improve the bioavailability, stability, and therapeutic efficacy of drugs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLiposomes\u003c\/strong\u003e are spherical vesicles composed of lipid bilayers (two layers of fat molecules). They are capable of encapsulating both hydrophilic (water-loving) and hydrophobic (water-fearing) drugs. Liposomes offer enhanced circulation times and reduced immune clearance when surface-modified with polyethylene glycol (PEG). This process is known as PEGylation. This modification enables liposomes to evade the immune system and achieve prolonged systemic circulation. Prolonged circulation is crucial for reaching target tissues like inflamed aneurysms.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMicelles\u003c\/strong\u003e are formed from the self-assembly of amphiphilic molecules (molecules with both water-loving and water-fearing parts) in aqueous environments. Micelles are particularly effective in solubilizing hydrophobic drugs and enhancing their bioavailability. Their small size allows for passive accumulation in inflamed or diseased tissues via the enhanced permeability and retention (EPR) effect. The EPR effect is a mechanism often leveraged in the treatment of conditions like intracranial aneurysms.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePolymeric nanoparticles\u003c\/strong\u003e are solid, biodegradable particles made from materials like polylactic acid (PLA) and poly(lactic co-glycolic acid) (PLGA). These nanoparticles provide the controlled release of encapsulated drugs. Controlled release ensures a sustained therapeutic effect over time. Their surfaces can be functionalized with targeting ligands (molecules that bind to specific targets) to improve the specificity of drug delivery. This allows them to bind selectively to cells or tissues associated with aneurysm pathogenesis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDendrimers\u003c\/strong\u003e are highly branched, nanoscale macromolecules with a well-defined, tree-like structure. Their surface groups can be modified with functional ligands to target specific cellular receptors. This increases the precision of drug delivery to aneurysmal tissues. Dendrimers are particularly useful for delivering multiple therapeutic agents simultaneously. This offers a platform for combination therapies.\u003c\/p\u003e\n\n\u003cp\u003eThese nanocarriers improve the pharmacokinetics (how the body processes drugs) and pharmacodynamics (how drugs affect the body) of therapeutic agents. They enhance drug delivery to difficult-to-reach areas, such as the brain, by overcoming biological barriers like the blood–brain barrier (BBB).\u003c\/p\u003e\n\n\u003cp\u003eIn the context of intracranial aneurysms, nanocarriers such as polymeric nanoparticles and liposomes offer promising solutions for the delivery of drugs like Edaravone and Tanshinone IIA. These drugs suffer from poor bioavailability and solubility. By encapsulating these drugs within nanocarriers, their stability and targeting potential can be significantly improved. This leads to better therapeutic outcomes.\u003c\/p\u003e\n\n\u003cp\u003eOne of the major challenges in nanocarrier-based drug delivery is evading the body's immune system. To circumvent immune detection, biomimetic coatings (coatings that mimic natural biological materials) are commonly employed. Among these, PEG is the most widely used polymer due to its non-toxic and biocompatible properties.\u003c\/p\u003e\n\n\u003cp\u003ePEGylation helps reduce opsonization (the process by which immune proteins coat particles for destruction), phagocytosis (cell eating), and nanoparticle aggregation. This prolongs the circulation time of nanocarriers in the bloodstream. However, an emerging concern is the development of anti-PEG antibodies.\u003c\/p\u003e\n\n\u003cp\u003eWhile some individuals may develop these antibodies following the administration of PEG-containing formulations, others may possess pre-existing antibodies. Studies in rodent models have shown that PEGylated liposomes can induce the production of these antibodies. These antibodies accelerate the clearance of PEG-coated nanoparticles, thereby reducing their therapeutic efficacy.\u003c\/p\u003e\n\n\u003cp\u003eIn addition to PEG, other biomimetic materials have been explored to further enhance immune evasion. These include platelet-derived coatings, red blood cell membranes, and macrophage membrane coatings. These alternative coatings aim to improve the biocompatibility and longevity of nanocarriers in circulation by mimicking the body's natural cellular components.\u003c\/p\u003e\n\n\u003cp\u003eThere are two primary targeting strategies for nanocarriers: active and passive targeting.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eActive targeting\u003c\/strong\u003e relies on the functionalization of nanocarrier surfaces with ligands that specifically bind to molecules overexpressed on the surface of target cells. These ligands can include peptides, small molecules, or antibodies designed to interact with receptors uniquely present or upregulated in the pathological tissue, such as inflamed aneurysms. By exploiting these molecular interactions, active targeting enhances the precision of drug delivery. This ensures that therapeutic agents accumulate predominantly at the desired site.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePassive targeting\u003c\/strong\u003e leverages the EPR effect, a phenomenon commonly observed in inflammatory and tumor tissues. In these environments, increased vascular permeability allows nanoparticles to accumulate more readily in diseased tissues without the need for specific ligand–receptor interactions. This method is particularly useful in conditions like aneurysms, where localized inflammation can facilitate nanoparticle penetration. However, passive targeting lacks the specificity of active targeting and may result in off-target effects. This limits its overall therapeutic efficacy.\u003c\/p\u003e\n\n\u003cp\u003eTogether, these strategies represent key avenues for improving the delivery of therapeutic agents in complex diseases like intracranial aneurysms. However, each approach is accompanied by its own set of limitations and challenges, including immune clearance and targeting precision. Further research into optimizing nanocarrier design, including surface modifications and biomimetic coatings, is crucial for overcoming these obstacles and enhancing clinical outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"monitoring\"\u003eMonitoring and Identifying Aneurysms at Risk of Rupture\u003c\/h2\u003e\n\n\u003cp\u003eThe effective identification and monitoring of intracranial aneurysms, particularly those at high risk of rupture, is an ongoing challenge in clinical practice. Macrophage infiltration has been shown to be strongly correlated with aneurysm rupture. This suggests that inflammatory processes are critical contributors to aneurysm instability.\u003c\/p\u003e\n\n\u003cp\u003eWhen comparing ruptured and unruptured aneurysms, macrophage infiltration is significantly more prevalent in the ruptured cases. This makes macrophage infiltration a valuable biomarker for identifying aneurysms likely to rupture.\u003c\/p\u003e\n\n\u003cp\u003eNanoparticles have emerged as useful tools for imaging aneurysms. Ultrasmall superparamagnetic iron oxide particles (USPIOs) are composed of an iron oxide core and a hydrophilic coating. USPIOs have demonstrated the ability to target and accumulate in macrophages.\u003c\/p\u003e\n\n\u003cp\u003eThis accumulation enables the use of USPIOs as contrast agents in magnetic resonance imaging (MRI). This facilitates the visualization of inflammatory activity within aneurysms. Among these particles, ferumoxytol, initially developed for the treatment of anemia in chronic kidney disease patients, has proven particularly effective for this purpose.\u003c\/p\u003e\n\n\u003cp\u003eFerumoxytol accumulates in macrophage-rich regions of aneurysm walls. Its presence within 24 hours of administration has been linked to aneurysms that are at high risk of rupture within the following six months.\u003c\/p\u003e\n\n\u003cp\u003eAs a diagnostic tool, ferumoxytol has an excellent safety profile. No significant adverse events have been reported in its approved use for anemia. However, when used repeatedly in aneurysm imaging, concerns regarding iron overload arise. Excessive iron deposition may lead to oxidative stress and damage to surrounding tissues. This requires further investigation into the long-term safety of repeated ferumoxytol use in this context.\u003c\/p\u003e\n\n\u003cp\u003eBeyond iron oxide nanoparticles, other nanomaterials have shown potential in aneurysm imaging. Immunoliposomes, which are liposomes functionalized with specific antibodies, provide another method for identifying high-risk aneurysms. By targeting α-smooth muscle actin (αSMA) on vascular smooth muscle cells (VSMCs) and CD31 on endothelial cells, these liposomes offer a dual-targeting approach.\u003c\/p\u003e\n\n\u003cp\u003eThe loss or dysfunction of VSMCs is a significant factor in aneurysm wall weakening. Endothelial dysfunction is closely associated with an increased rupture risk. Through these specific targeting mechanisms, immunoliposomes can identify regions undergoing both structural remodeling and endothelial degradation. These are strong indicators of aneurysm instability.\u003c\/p\u003e\n\n\u003cp\u003eAdditionally, these liposomes can be loaded with contrast agents such as gadolinium. This further enhances their visibility in MRI scans. It provides a comprehensive imaging modality that combines both inflammatory and structural markers.\u003c\/p\u003e\n\n\u003cp\u003eDespite the promising advancements in the use of USPIOs, immunoliposomes, and other nanomaterials for aneurysm imaging, several limitations and risks must be acknowledged. Iron oxide nanoparticles, such as ferumoxytol, raise concerns about long-term iron accumulation in tissues. While ferumoxytol has been deemed safe for anemia treatment, the potential for iron overload through repeated imaging applications remains a significant issue. Excessive iron in the body can catalyze the formation of reactive oxygen species (ROS). This leads to oxidative damage and inflammation, particularly in patients with impaired iron clearance.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, gold nanoparticles (AuNPs), which have been explored for use in computed tomography (CT) imaging, present their own set of challenges. Although these nanoparticles provide excellent contrast due to their high electron density, their tendency to accumulate in non-target tissues raises questions. These non-target tissues include the liver and spleen. The accumulation raises questions about their long-term safety and biocompatibility. The slow clearance of gold nanoparticles from the body could result in chronic exposure and potential toxicity. This limits their widespread use in clinical applications.\u003c\/p\u003e\n\n\u003cp\u003eSimilarly, quantum dots (QDs), renowned for their fluorescence and use in optical imaging, are associated with risks due to their heavy metal content, particularly cadmium. The release of toxic components from QDs, especially in the harsh oxidative environment of aneurysm walls, could lead to significant cytotoxicity (cell damage). The development of biodegradable alternatives is necessary to mitigate these risks while maintaining the advantages offered by QDs in terms of imaging sensitivity and resolution.\u003c\/p\u003e\n\n\u003cp\u003eAddressing these challenges requires the development of biodegradable nanomaterials that can be safely metabolized and cleared from the body after their diagnostic role is fulfilled. Polymeric nanoparticles, which degrade into non-toxic byproducts, offer a promising alternative to metal-based nanoparticles.\u003c\/p\u003e\n\n\u003cp\u003eFurthermore, the combination of theranostic nanocarriers, which integrate both therapeutic and diagnostic functions, could provide real-time feedback on the aneurysm status while simultaneously delivering treatments to reduce rupture risk. This dual functionality would allow for the more precise and efficient management of aneurysms, potentially improving patient outcomes.\u003c\/p\u003e\n\n\u003cp\u003eThe use of nanomaterials such as USPIOs, gold nanoparticles, and immunoliposomes in aneurysm imaging has demonstrated significant potential in identifying aneurysms at a high risk of rupture.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis review suggests that nanoparticles could change how doctors treat brain aneurysms in the future. Currently, treatment options for unruptured aneurysms include watching and waiting, surgical clipping, or endovascular coiling. For ruptured aneurysms, endovascular treatment has become the primary method of management.\u003c\/p\u003e\n\n\u003cp\u003eNanoparticles offer a potential new way to deliver drugs directly to the aneurysm wall. This could help reduce inflammation and strengthen the vessel wall, potentially lowering the risk of rupture. The ability to target specific molecules involved in aneurysm development means that treatment could be more precise and cause fewer side effects.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, this research could eventually lead to:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eNew drug treatments that can reach the aneurysm without invasive surgery\u003c\/li\u003e\n\u003cli\u003eBetter imaging tools to identify which aneurysms are most likely to rupture\u003c\/li\u003e\n\u003cli\u003ePersonalized treatment plans based on the specific characteristics of each patient's aneurysm\u003c\/li\u003e\n\u003cli\u003eCombined diagnostic and therapeutic approaches (theranostics) that allow doctors to monitor treatment response in real time\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe drugs Edaravone and Tanshinone IIA, when combined with nanocarriers, could provide neuroprotective (brain-protecting) and anti-inflammatory benefits. These drugs currently have poor bioavailability and solubility, meaning they are hard to deliver effectively to the brain. Nanocarriers could solve this problem.\u003c\/p\u003e\n\n\u003cp\u003eThe review also highlights that inflammation plays a central role in aneurysm development and rupture. This means that anti-inflammatory treatments, delivered precisely to the aneurysm site, could be a promising strategy.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations and Challenges\u003c\/h2\u003e\n\n\u003cp\u003eThe review acknowledges several limitations and challenges that must be addressed before nanocarrier-based treatments become available to patients.\u003c\/p\u003e\n\n\u003cp\u003eFirst, the immune system can clear nanoparticles from the body before they reach their target. PEGylation helps reduce this clearance, but some patients develop anti-PEG antibodies that accelerate nanoparticle removal. This reduces therapeutic efficacy.\u003c\/p\u003e\n\n\u003cp\u003eSecond, passive targeting lacks specificity and may cause off-target effects. Active targeting is more precise but requires identifying specific molecules that are unique to the aneurysm tissue.\u003c\/p\u003e\n\n\u003cp\u003eThird, some nanomaterials used for imaging have safety concerns. Iron oxide nanoparticles like ferumoxytol can cause iron overload with repeated use. Gold nanoparticles accumulate in the liver and spleen and clear slowly from the body. Quantum dots contain heavy metals like cadmium that can be toxic.\u003c\/p\u003e\n\n\u003cp\u003eFourth, the review notes that macrophages may not be the only key factor in aneurysm development. Some studies suggest that loss of collagen in the aneurysm wall is associated with increased rupture risk, independent of macrophage activity. This means that targeting only inflammation may not be enough.\u003c\/p\u003e\n\n\u003cp\u003eFifth, most of the studies discussed in this review were conducted in animal models or in laboratory settings. More research is needed to confirm whether these findings apply to human patients.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Future Directions\u003c\/h2\u003e\n\n\u003cp\u003eThe authors propose several directions for future research and clinical development.\u003c\/p\u003e\n\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eDevelop biodegradable nanomaterials\u003c\/strong\u003e that can be safely metabolized and cleared from the body after their diagnostic or therapeutic role is complete. Polymeric nanoparticles are a promising alternative to metal-based nanoparticles.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOptimize nanocarrier design\u003c\/strong\u003e by improving surface modifications and biomimetic coatings. This includes exploring alternatives to PEG, such as platelet-derived coatings, red blood cell membranes, and macrophage membrane coatings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestigate theranostic nanocarriers\u003c\/strong\u003e that combine therapeutic and diagnostic functions. These could provide real-time feedback on aneurysm status while delivering treatment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eConduct long-term safety studies\u003c\/strong\u003e on repeated use of imaging nanoparticles, particularly ferumoxytol, to assess the risk of iron overload.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExplore combination therapies\u003c\/strong\u003e that target both inflammation and structural weakening of the aneurysm wall.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTranslate findings from animal models to human clinical trials\u003c\/strong\u003e to confirm safety and efficacy.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors emphasize that an interdisciplinary approach is essential. This approach combines knowledge from neurosurgery, vascular biology, nanotechnology, and immunology. By learning from how other aneurysms, such as aortic aneurysms, are treated, researchers can find new ideas that could be applied to brain aneurysms.\u003c\/p\u003e\n\n\u003cp\u003eThe review concludes that nanoparticles have the potential to positively influence the management of intracranial aneurysms. This paves the way for personalized treatment options that could significantly improve patient outcomes.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is a cerebral aneurysm?\u003c\/h3\u003e\n\u003cp\u003eA cerebral aneurysm is an abnormal bulge in an artery in the brain. They most often form at branching points of the Circle of Willis, a ring of blood vessels at the base of the brain. Most occur in the front part of the brain. About 1 to 5 in 100 people have one.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risk factors for developing a cerebral aneurysm?\u003c\/h3\u003e\n\u003cp\u003eRisk factors include atherosclerosis (hardening of the arteries), alcohol abuse, smoking, and hypertension (high blood pressure). These factors can weaken the artery wall over time. Having one or more of these risk factors may increase the chance of developing an aneurysm, but many people with aneurysms have no known risk factors.\u003c\/p\u003e\n\u003ch3\u003eWhat is the risk of an aneurysm rupturing?\u003c\/h3\u003e\n\u003cp\u003eFor unruptured aneurysms, the yearly risk of rupture is about 0.7%. This risk increases with the size and location of the aneurysm, and with patient factors such as high blood pressure and smoking history. Rupture causes bleeding around the brain, which has high rates of death and disability.\u003c\/p\u003e\n\u003ch3\u003eHow are unruptured aneurysms currently managed?\u003c\/h3\u003e\n\u003cp\u003eCurrent practices for managing unruptured intracranial aneurysms increasingly favor endovascular treatment, which treats the aneurysm from inside the blood vessel. Other options include watching and waiting or surgical clipping. For ruptured aneurysms, endovascular treatment has become the primary method of management.\u003c\/p\u003e\n\u003ch3\u003eWhat are nanocarriers and how might they help treat aneurysms?\u003c\/h3\u003e\n\u003cp\u003eNanocarriers are tiny delivery vehicles, such as liposomes and polymeric nanoparticles, that can carry drugs directly to the aneurysm wall. They may overcome the blood–brain barrier and reduce side effects. In research, they have delivered drugs like Edaravone and Tanshinone IIA, which normally have poor solubility and bioavailability.\u003c\/p\u003e\n\u003ch3\u003eCan nanoparticles help identify aneurysms at high risk of rupture?\u003c\/h3\u003e\n\u003cp\u003eYes, some nanoparticles are being studied for imaging. For example, ferumoxytol, an iron oxide particle, accumulates in macrophage-rich areas of the aneurysm wall. In research, its presence within 24 hours of administration has been linked to aneurysms at high risk of rupture within the following six months. However, repeated use raises concerns about iron overload.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main challenges before nanoparticle treatments are available?\u003c\/h3\u003e\n\u003cp\u003eChallenges include immune clearance of nanoparticles, lack of specificity with passive targeting, and safety concerns for some imaging materials. Also, most studies were done in animals or labs, so more research is needed in humans. Targeting only inflammation may not be enough because collagen loss also weakens the wall.\u003c\/p\u003e\n\u003ch3\u003eI have an unruptured brain aneurysm and my doctor recommends endovascular treatment — when should I get a second opinion?\u003c\/h3\u003e\n\u003cp\u003eBecause the annual rupture risk for unruptured aneurysms is about 0.7% but rises with size, location, hypertension and smoking, and because management has increasingly favored endovascular options, a second opinion is reasonable before committing to treatment. It can review whether watching and waiting, surgical clipping, or endovascular coiling fits your aneurysm's characteristics, and whether newer nanoparticle-based drug delivery or imaging approaches might apply. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Cerebral Aneurysm: Filling the Gap Between Pathophysiology and Nanocarriers.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Toader C, Radoi MP, Covlea CA, Covache-Busuioc RA, Ilie MM, Glavan LA, Corlatescu AD, Costin HP, Gica MD, Dobrin N.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Department of Neurosurgery, \"Carol Davila\" University of Medicine and Pharmacy, Bucharest, Romania; Department of Vascular Neurosurgery, National Institute of Neurology and Neurovascular Diseases, Bucharest, Romania; \"Nicolae Oblu\" Clinical Hospital, Iasi, Romania\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e International Journal of Molecular Sciences (Int. J. Mol. Sci.) 2024, Volume 25, Article 11874\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Received: 20 August 2024; Revised: 24 October 2024; Accepted: 28 October 2024; Published: 5 November 2024\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e https:\/\/doi.org\/10.3390\/ijms252211874\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e nanoparticles; intracranial aneurysms; pathophysiology; nanocarriers; inflammation; endothelial dysfunction; drug delivery\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace consultation with a qualified healthcare provider. Patients with questions about cerebral aneurysms should discuss their individual situation with their doctor.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47797570994332,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-nanoparticles-for-brain-aneurysms-new-hope-for-treatment-hero.png?v=1791955224","url":"https:\/\/diagnosticdetectives.kr\/products\/nanoparticles-for-brain-aneurysms-new-hope-for-treatment","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}